STOCK TITAN

Salarius Pharmaceuticals Inc - SLRX STOCK NEWS

Welcome to our dedicated page for Salarius Pharmaceuticals news (Ticker: SLRX), a resource for investors and traders seeking the latest updates and insights on Salarius Pharmaceuticals stock.

Salarius Pharmaceuticals Inc (NASDAQ: SLRX) is a clinical-stage biotechnology company pioneering targeted therapies for cancers with high unmet medical needs. This page serves as the definitive source for verified news and official updates, providing stakeholders with timely insights into the company's progress in oncology drug development.

Investors and researchers will find curated press releases covering clinical trial milestones, regulatory developments, and strategic partnerships. Key focus areas include updates on Salarius' protein degradation therapies and inhibitor candidates, financial disclosures, and collaborative research initiatives in precision medicine.

All content is rigorously sourced from SEC filings, corporate communications, and validated industry reports. The repository is maintained to support informed analysis while adhering to financial compliance standards. Bookmark this page for efficient tracking of SLRX's advancements in addressing gene dysregulation through innovative biopharmaceutical approaches.

Rhea-AI Summary

Salarius Pharmaceuticals (Nasdaq: SLRX) announced agreements with institutional investors to exercise outstanding warrants, raising approximately $3.5 million by issuing 3,964,065 shares. This follows their public offering in February 2020. The exercised warrants' price was reduced from $1.15 to $0.90 to encourage immediate cash exercise. New warrants will allow the purchase of additional shares at $1.182, exercisable in six months. The funds will support the development of seclidemstat, focusing on pediatric and solid tumors, with key milestones expected in early 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.34%
Tags
none
-
Rhea-AI Summary

Salarius Pharmaceuticals (Nasdaq: SLRX) announced a $0.8 million payment under its contract with the Cancer Prevention and Research Institute of Texas (CPRIT), part of a total expected of $1.7 million. This funding supports the development of seclidemstat, its lead drug candidate, being evaluated in clinical trials for Ewing sarcoma and advanced solid tumors. Salarius aims to achieve several milestones, including determining the maximum tolerated dose in the Ewing sarcoma trial and expanding the study to include related sarcomas. Total CPRIT disbursements will reach $11.3 million with this funding.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.07%
Tags
none
-
Rhea-AI Summary

Salarius Pharmaceuticals (Nasdaq: SLRX) announced CEO David Arthur's participation in A.G.P.’s Virtual Healthcare Symposium on November 19, 2020. The focus will be on their lead drug candidate, seclidemstat, an oral medication targeting lysine-specific demethylase 1 (LSD1), crucial in some cancers. Ongoing Phase 1/2 trials for seclidemstat involve patients with refractory Ewing sarcoma and advanced solid tumors. Notably, one patient showed over 80% reduction in target lesions after six months of treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
conferences
Rhea-AI Summary

Salarius Pharmaceuticals (Nasdaq: SLRX) reported its Q3 2020 financial results, revealing a net loss of $1.7 million, or $0.10 per share, significantly reduced from a loss of $2.6 million or $0.73 per share year-over-year. The company’s cash position improved to $9.6 million, aided by a $6.2 million public offering in August 2020. The Ewing sarcoma clinical trial is progressing, with plans to enter the Phase 2 dose-expansion stage in Q1 2021 and an expansion to include Ewing-related sarcomas. Salarius aims to leverage these developments for future growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.14%
Tags
-
Rhea-AI Summary

Salarius Pharmaceuticals (SLRX) announced a conference call on November 11, 2020, at 4:30 p.m. ET to discuss its third-quarter 2020 corporate and financial results. Investors can join the call by dialing (833) 423-0481 or (918) 922-2375 with Conference ID 1277839. An audio webcast will also be available on the company's website. Salarius focuses on developing cancer therapies, including its lead candidate, seclidemstat, which is in clinical trials for pediatric and other cancers and has received multiple designations from the FDA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
conferences earnings
-
Rhea-AI Summary

Salarius Pharmaceuticals announced that CEO David Arthur will present at the BIO Investor Forum Digital from October 13 to 15, 2020. The presentation, available on demand, will cover the company's business overview, recent achievements, and milestones for their lead candidate seclidemstat. This reversible LSD1 inhibitor is currently in Phase 1/2 trials for Ewing sarcoma, a rare pediatric cancer, and advanced solid tumors. The presentation will also include details on Salarius' regulatory designations and ongoing clinical programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
conferences
Rhea-AI Summary

Salarius Pharmaceuticals (Nasdaq: SLRX) has announced participation in two investor conferences in September 2020. CEO David Arthur will present the company's business model, recent achievements, and upcoming milestones, particularly highlighting seclidemstat, their leading drug candidate in Phase 1/2 trials for Ewing sarcoma and advanced solid tumors. The presentations are scheduled for September 16 and 17, 2020, with live webcasts available. Salarius, focusing on oncological treatments, has received Fast Track and Orphan Drug Designations from the FDA, showcasing its commitment to addressing critical cancer needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
conferences
-
Rhea-AI Summary

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) announced that CEO David Arthur will present at the 2020 LD 500 Conference, taking place virtually from September 1-4, 2020. Arthur's presentation will cover Salarius' business overview and recent clinical achievements, particularly for its lead compound, seclidemstat, a reversible LSD1 inhibitor currently in Phase 1/2 trials for Ewing sarcoma and advanced solid tumors. The presentation is scheduled for September 1 at 3:20 PM ET, with a live webcast available for attendees.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
conferences
-
Rhea-AI Summary

Salarius Pharmaceuticals (Nasdaq: SLRX) reported significant developments following a $6.2 million public offering closed on August 3, 2020. The company recorded a net loss of $1.8 million for Q2 2020, down from $0.9 million in the previous year, with increased R&D and administrative costs contributing to losses. Salarius is expanding its clinical trial for seclidemstat to include Ewing-related sarcomas, supported by promising preliminary data. Current cash reserves stand at $7.2 million, with additional funding opportunities available through the CPRIT contract.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.67%
Tags
Rhea-AI Summary

Salarius Pharmaceuticals (SLRX) announced a conference call on August 12, 2020, at 4:30 p.m. ET, to present its Q2 2020 corporate and financial results. The company is focused on treating cancers linked to dysregulated gene expression, with its lead candidate, seclidemstat, in Phase 1/2 trials, specifically for Ewing sarcoma.

Salarius has received several designations from the FDA, including Fast Track and Orphan Drug Designations. The company also secured financial support for its clinical programs, including an $18.7 million award from CPRIT.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.88%
Tags
conferences earnings
Salarius Pharmaceuticals Inc

Nasdaq:SLRX

SLRX Rankings

SLRX Stock Data

1.17M
1.71M
2.1%
4.8%
5.41%
Biotechnology
Pharmaceutical Preparations
Link
United States
HOUSTON